Abstract
Introduction

Smooth muscle cells regulate the diameter of hollow organs and are effectors of fibroproliferative remodelling in several disease states. In this regard, bronchial smooth muscle cells regulate airway diameter and play a key role in lung function and airway
hyperresponsiveness in asthma [1] . Structural and phenotypic alterations in airway smooth muscle are frequently observed in asthma and include increased airway smooth muscle mass and increased abundance of contractile phenotype marker proteins. [2] [3] [4] .
Phenotype plasticity of airway smooth muscle is regulated by external stimuli such as growth factors (e.g. transforming growth factor [TGF]-␤1) and the extracellular matrix, that signal through a network of intracellular cascades to control the transcription and translation of smooth muscle-specific genes
A feature of mature, contractile airway smooth muscle is the presence of abundant caveolae, plasma membrane invaginations that regulate a variety of physiological functions including myocyte contraction and cell proliferation [5] [6] [7] [8] . Caveolae in smooth muscle are characterized by the presence of caveolin-1 and caveolin-2 [9] as well as the more recently described cavin family members including polymerase I and transcript release factor (PTRF)/cavin-1 [10, 11] . Caveolin-1 and cavin-1 interact at the plasma membrane which is required for caveola formation [10] . Caveolae exhibit a highly ordered linear array distribution on contractile smooth muscle cells; this because of indirect tethering to the actin cytoskeleton via direct binding of caveolin-1 to ␤-dystroglycan, which is also a contractile phenotype marker protein [12] [13] [14] [15] . Increased caveolin-1 and caveolae abundance in mature myocytes likely maintains a mitotically quiescent phenotype, as disruption of caveolae, or caveolin-1 knockdown is sufficient to activate p42/p44 MAP kinase signalling and cell proliferation [6] . [16] [17] [18] [19] . The association of RTK with caveolae and caveolin-1 in airway smooth muscle is reversible, as mitogen stimulation induces the release of caveolin-1 from the activated RTK which facilitates RTK trafficking to non-caveolae membrane [6, 20] 
Caveolin-1 functionally represses myocyte proliferation via its caveolin scaffolding domain that binds to (receptor) tyrosine kinases (RTKs), such as epidermal growth factor receptor, platelet-derived growth factor receptor and Src
. Caveolin-1 thus plays an important role in maintaining airway myocyte quiescent, which is a hallmark of contractile phenotype cells. The functional role of increased caveolae and caveolin-1 in contractile phenotype smooth muscle cells is not fully established. It may support molecular signalling associated with contraction, as for most smooth muscles, disruption of caveolae or caveolin-1 knockdown is sufficient to reduce agonist-induced Ca 2ϩ
responses and contraction [5, 7, 8, [21] [22] [23] [24] [25] [26] [27] [28] . Indeed, airway smooth muscle contraction and Ca 2ϩ signalling in response to the bronchoconstrictor agents methacholine, histamine and bradykinin requires intact caveolae, and the receptors and G proteins that regulate contraction in response to these agents are localized to caveolae [5, 7, 8] . In addition, a recent study indicates that the expression of dystrophin, ␤-dystroglycan, ␤-, ␦-andsarcoglycan, which localize to caveolae in airway smooth muscle, is tightly correlated with the expression of contractile phenotype markers and caveolin-1 [14, 15] 
Materials and methods
Cell culture
Canine and human airway smooth muscle cells were used for cell culture studies. Primary cultured canine airway myocytes were established from dissociated canine trachealis as we have described previously [36, 37] . Human bronchial smooth muscle cell lines immortalized by stable expression of human telomerase reverse transcriptase were prepared as described previously [6, 38] 
siRNA transfection
The small interfering RNA (siRNA) Generation Kit (Gene Therapy Systems, San Diego, CA, UDA) was used to prepare dicer-generated siRNA from human airway smooth muscle cDNA as we have described previously [38] with primers that amplified caveolin-1 (forward 5Ј-GTAGACTCGGAGGGA- 
CATC-3Ј; reverse 5Ј-GTCCGCATCAACTTGCAG-3Ј). Primer sequences also included the 52-bp T7 promoter sequence linkers (5Ј-GCGTAATACGACT-CACTATAGGGAGA-target DNA-3Ј), which were incorporated into the DNA template PCR product to allow for in vitro transcription with the TurboScript T7 Transcription Kit (Gene Therapy Systems
Results
Caveolin-1 is preferentially expressed by contractile phenotype airway myocytes
We previously reported that proliferating human airway smooth muscle cells in culture express reduced levels of caveolin-1 protein [6] . We first confirmed the preferential expression of caveolin-1 in cell culture conditions that promote acquisition of a contractile phenotype that is characterized by enhanced expression of marker proteins such as sm-MHC, sm-␣-actin and calponin [44] . Immunoblot analysis of caveolin-1 abundance in 7 day serum deprived human airway smooth muscle cultures revealed it was increased approximately 2-fold compared to myocytes in proliferating cultures (Fig. 1A) [36] . As confirmed in Figure 1B, Fig. 2A ) (Fig. 3A, [6, 7] ). Notably, this reduction in caveolin-1 expression is quantitatively similar in magnitude to the opposing increase in caveolin-1 expression that we observe when proliferating myocytes are subjected to prolonged serum withdrawal (Fig. 1A) . Indeed we previously reported that this level of caveolin-1 silencing is sufficient to promote spontaneous p42/p44 MAP kinase activation and cell proliferation of airway smooth muscle cells [6] . To 
. Concentration response relationships of TGF-␤1 after 2 days of treatment indicated that the induction of calponin and sm-␣-actin expression was submaximal at a concentration of 1 ng/ml (Fig. 2B-D). Notably, TGF-␤1 treatment did not augment spontaneously increased caveolin-1 expression during serum deprivation at any of the time-points or concentrations studied (Fig. 2E). Because 2 days of TGF-␤1 treatment with 1 ng/ml was found to induce sub-maximal induction of contractile protein expression, this condition was used in all further experiments.
To investigate whether caveolin-1 expression by airway smooth muscle was required for contractile phenotype maturation induced by TGF-␤1, we next employed an siRNA knockdown strategy to reduce caveolin-1 expression. Initial experiments indicated that caveolin-1 expression was clearly reduced by siRNA treatment 48 hrs after transfection with maximal reduction of ~50% being reached at 72 hrs
Fig. 2 TGF-␤1 induces contractile phenotype marker expression in airway smooth muscle. (A) Human airway smooth muscle cells were grown to confluence, serum-deprived for 2 days and subsequently treated for 2, 4 or 7 days in F-12 media with 10 ng/ml TGF-␤1, as indicated. Cell lysates were then prepared and Western analysed for the expression of sm-␣-actin, calponin, caveolin-1 or ␤-actin. (B) Human airway smooth muscle cells were grown to confluence, serum-deprived for 2 days in F-12 media, followed by 2 days treatment w increasing concentrations (0.1-10 ng/ml) of TGF-␤1, as indicated. Cell lysates were then prepared and analysed by Western blot for the expression of sm-␣-actin, calponin, caveolin-1 or ␤-actin. Expression of (C) sm-␣-actin, (D) calponin and (E) caveolin-1 was also analysed by densitometry and normalized to the maximal response induced by TGF-␤1, which was set at 100%. ␤-actin expression was used to correct for small differences in protein loading.
induce contractile phenotype marker expression by airway smooth muscle (Fig. 3) [37, 47, 48] . Indeed, TGF-␤1 induced the phosphorylation of 4E-BP1 in a concentration dependent manner (Fig. 4A) . Interestingly, caveolin-1 knockdown using either the Fig. 4B and C) . These results were confirmed using the Cav-1 silence human airway smooth muscle cell line that exhibits (Fig. 4D) . 
Fig. 3 Caveolin-1 knockdown reduces TGF-␤1 induced contractile phenotype marker expression. (A) Human airway smooth muscle cells were grown to 70-80% confluence and then serum-deprived in F-12 media. Concomitant with serum-deprivation, cells were transfected with an siRNA directed against caveolin-1 and maintained in culture for up to 4 days. Cell lysates were then prepared and analysed for caveolin-1 and ␤-actin content. (B) Human airway smooth muscle cells were grown to 70-80% confluence and then serum-deprived in F-12 media for 2 days. Concomitant with serumdeprivation, cells were transfected with either a commercially available siRNA directed against caveolin-1 or a dicer-generated siRNA mix directed against caveolin-1. Cells treated with transfection reagent alone served as controls (vehicle). Caveolin-1 knockdown was allowed to occur for 2 days in serum-free F-12 media, after which cells were treated with TGF-␤1 (1 or 10 ng/ml, as indicated) for another 2 days. Cell lysates were then prepared and analysed for sm-␣-actin, calponin and ␤-actin content. Expression of (C) sm-␣-actin and (D) calponin was analysed by densitometry and normalized to the maximal response induced by TGF-␤1, which was set at 100%. ␤-actin expression was used to correct for small differences in
Ͼ60% reduced expression of caveolin-1 protein. Our findings show that constitutive suppression of caveolin-1 expression markedly limits capacity for TGF-␤1-induction of sm-␣-actin expression and 4E-BP1 phosphorylation
Fig. 4 Caveolin-1 knockdown reduces TGF-␤1 induced 4EBP-1 phosphorylation. (A) Human airway smooth muscle cells were grown to confluence and subsequently serum-deprived for 2 days in F-12 media in the absence or presence of increasing concentrations (0.1-10 ng/ml) of TGF-␤1, as indicated. Cell lysates were then prepared and Western analysed for the expression of phospho-(Thr37/46)-4E-BP-1, total 4E-BP-1 and ␤-actin content. (B) Human airway smooth muscle cells were grown to 70-80% confluence and then serum-deprived in F-12 media for 2 days. Concomitant with serum-deprivation, cells were transfected with a dicer-generated siRNA mix directed against caveolin-1. Cells treated with transfection reagent alone served as controls (vehicle). Caveolin-1 knockdown was allowed to occur for 2 days in serum-free F-12 media, after which cells were treated with TGF-␤1 (1 ng/ml) for another 2 days. Cell lysates were then prepared and analysed for phospho-(Thr37/46)-4E-BP-1, total 4E-BP-1 and ␤-actin content. (C) Human airway smooth muscle cells were grown to 70-80% confluence and then serum-deprived in F-12 media for 2 days. Cells were transfected with either a commercially available siRNA directed against caveolin-1 or a dicer-generated siRNA directed against caveolin-1. Cells treated with transfection reagent alone served as controls (vehicle). Caveolin-1 knockdown was allowed to occur for 2 days in serum-free F-12 media, after which cells were treated with TGF-␤1 (1 or 10 ng/ml, as indicated) for another 2 days. Cell lysates were then prepared and analysed for phospho-(Thr37/46)-4E-BP-1, total 4E-BP-1 and ␤-actin content. Expression of phospho-(Thr37/46)-4E-BP-1 was analysed by densitometry and normalized to the maximal response induced by TGF-␤1
Caveolin-1 expression is increased in smooth muscle after allergen challenge in guinea pigs
Our current results and published data [6] [7] [8] [43] . Guinea pigs repeatedly challenged with ovalbumin develop airway hyperresponsiveness, airway smooth muscle thickening, increased pulmonary contractile protein expression and increased contractile capacity of airway smooth muscle [41] . Thus, to determine whether our in vitro findings were related to increased contractile airway smooth muscle mass in vivo, we determined caveolin-1 expression by airway smooth muscle using guinea pigs subjected to repeated allergen exposure. As demonstrated in Figure 5A and B, Western analysis of whole lung indicated that repeated allergen exposures increased caveolin-1 expression. The increase in caveolin-1 was due, in part, to a specific increase in its expression by the airway smooth muscle, as determined using quantitative immunohistochemistry (Fig. 6A and   B) . These data mimic these we have reported for contractile phenotype marker proteins [42, 43] [7, 8, 21, 22, 24, 25] caveolae [6, 16, 19, 54] . 
